Table 1. Characteristics of group A (montelukast-placebo group) and group B (placebo-montelukast group).
| Group A (n=22) |
Group B (n=21) |
P value | |
|---|---|---|---|
| Male (%) | 11 (50) | 10 (47.6) | 1.00 |
| Age (month) | 48.8±17.2 | 41.2±15.1 | 0.13 |
| Severity of atopic dermatitis (%) | 0.55 | ||
| Moderate | 9 (40.9) | 11 (52.4) | |
| Severe | 13 (59.1) | 10 (47.6) | |
| Accompanying allergic disease (%) | |||
| Asthma | 4 (18.2) | 2 (9.5) | 0.66 |
| Allergic rhinitis | 16 (72.7) | 13 (61.9) | 0.53 |
| Atopy (%) | 15 (68.2) | 16 (76.2) | 0.74 |
| Aeroallergen sensitization (%) | 11/21 (52.4) | 11 (52.4) | 1.00 |
| Polysensitization (%) | 2/14 (14.3) | 2/16 (12.5) | 1.00 |
| Total IgE (kU/L) | 871.1±2,208.3 | 435.2±601.1 | 0.39 |
| ECP (µg/L) | 22.8±22.8 | 15.9±16.9 | 0.27 |
IgE, immunoglobulin E; ECP, eosinophil cationic protein.